RYARZIL Trademark

Trademark Overview

On Thursday, September 17, 2020, a trademark application was filed for RYARZIL with the United States Patent and Trademark Office. The USPTO has given the RYARZIL trademark a serial number of 90188978. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 8, 2024. This trademark is owned by Eagle Pharmaceuticals Inc.. The RYARZIL trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for treatment of nerve agent exposure and acute radiation syndrome

General Information

Serial Number90188978
Word MarkRYARZIL
Filing DateThursday, September 17, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 12, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for treatment of nerve agent exposure and acute radiation syndrome

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 27, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEagle Pharmaceuticals Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWoodcliff Lake, NJ 07677
Party NameEagle Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWoodcliff Lake, NJ 07677

Trademark Events

Event DateEvent Description
Monday, September 21, 2020NEW APPLICATION ENTERED
Tuesday, October 27, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, January 27, 2021ASSIGNED TO EXAMINER
Wednesday, February 3, 2021PRIORITY ACTION WRITTEN
Wednesday, February 3, 2021PRIORITY ACTION E-MAILED
Wednesday, February 3, 2021NOTIFICATION OF PRIORITY ACTION E-MAILED
Tuesday, August 3, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, August 3, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 3, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 3, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 22, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 12, 2021PUBLISHED FOR OPPOSITION
Tuesday, October 12, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 7, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, June 6, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, June 6, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, June 6, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, June 6, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, June 6, 2022SOU TEAS EXTENSION RECEIVED
Monday, June 6, 2022SOU EXTENSION 1 FILED
Monday, June 6, 2022SOU EXTENSION 1 GRANTED
Wednesday, June 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 7, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, December 7, 2022SOU EXTENSION 2 FILED
Wednesday, December 7, 2022SOU EXTENSION 2 GRANTED
Friday, December 9, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 5, 2023SOU TEAS EXTENSION RECEIVED
Monday, June 5, 2023SOU EXTENSION 3 FILED
Monday, June 5, 2023SOU EXTENSION 3 GRANTED
Tuesday, June 6, 2023ASSIGNED TO EXAMINER
Wednesday, June 7, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 8, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, January 8, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

ryarzil pharmaceutical preparations acute syndrome exposure radiation nerve namely treatment agent